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Abbreviations 
MSC  = Mesenchymal stem cell 
MN  = normal growth medium 
MO  = osteogenic medium 
GFP  = green fluorescence protein 
Ad.GFP = adenoviral vector carrying the green fluorescent protein gene 
BMP  = bone morphogenetic protein 
Ad.BMP-2 = adenoviral vector carrying the bone morphogenetic protein gene 
pfu  = plaque forming units 
DMEM = Dulbecco ś modified eagles medium 
PBS  = phosphate buffered saline 
WST-1 = water-soluble tetrazolium-1 
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HEK  = human embryonic kidney 
ELISA  = enzyme-linked immunosorbent assay 
ALP   = alkaline phosphatase  
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Introduction 
Bone fractures and bone defects occur in a variety of accidents, including traffic 
accidents, slip and fall accidents and other traumatic accidents. Clinical treatment with 
surgical or conservative therapies aims at obtaining bone healing with maximum 
functional recovery.  However, delayed unions and non-unions are still presented the 
common complications, especially among long bone fractures. Up to 5%-10% of bone 
fractures will develop a non-union (Kostenuik & Mirza, 2017; Panteli, Pountos, Jones, 
& Giannoudis, 2015), depending on the location and severity of the bone injury, soft 
tissue and vascular damage, the treatment for which remains great clinical challenges 
around the world.  
Autologous bone grafts have been considered as “gold standard” for large critical bone 
defects and non-unions because of their osteoinductive and osteoconductive properties 
(Heiple, Chase, & Herndon, 1963; Rogers & Greene, 2012; Ryzewicz et al., 2009). 
However, the limited supply and associated donor site morbidity constrain its further 
clinical application. Despite various research and methods have been investigated to 
develop new effective treatment strategies that can replace the current gold standard, 
little progress having been made.  
Mesenchymal stem cells (MSCs) have gained steady attention in the field of tissue 
engineering and regenerative medicine due to their multi-directional differentiation 
potential. Under specific differentiation conditions, MSCs are capable to differentiate 
into bone, cartilage, as well as muscle, fat and other soft tissues. In many cell-based 
tissue engineering studies for bone repair, MSCs in combination with various novel 
scaffolds have shown their promising achievements (del Rosario, Rodríguez-Évora, 
Reyes, Delgado, & Évora, 2015; J. J. Li, Roohani‐Esfahani, Kim, Kaplan, & Zreiqat, 
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2017; Niu et al., 2015; Schütz et al., 2017). However, cell isolation and time-consuming 
expansion procedures prior implantation obviously increase the cost and may induce 
the risk of contamination (Aslan et al., 2006). In addition, the cell-based tissue 
engineering approach has very high demands for scaffolds in terms of material and 
property to provide a suitable microenvironment for cell migration, proliferation and 
differentiation (Tolar et al., 2007). The complexity of such cell-based approaches 
challenges their practical translation.  
The improved strategy is utilizing tissue grafts instead of stem cells, so that the 
procedure of cell isolation and propagation could be avoided. This clearly simplifies 
the previous cell-based therapies and therefore are better suited for a clinical application. 
As indicated by Betz et al. (O. B. Betz et al., 2009; V. M. Betz et al., 2016), large 
segmental bone defects could be healed by the implantation of bone morphogenetic 
protein (BMP) gene activated fat tissue grafts. Despite fat tissue is recognized as the 
tissue source of adipose derived stem cells (ADSCs), whether gene activated fat tissue 
implant can transdifferentiate into bone is still unknown, while it could also be 
explained by that the gene transduced tissue implant merely serves as molecule signals 
delivery system, which mobilize host stem cells or progenitor cells to the injury site and 
then activate the body’s own regenerative capacity.  
In the publication 1, our study was designed to investigate the osteogenic 
transdifferentiation potential of human fat tissue under an osteogenic stimulus in vitro. 
Additionally, the capacity of three recombinant growth factors BMP -2, BMP-7 and 
BMP-9 to induce osteogenic transdifferentiation of adipose tissue was explored and 
compared.  
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The result demonstrated for the first time that human fat tissue is capable to undergo 
osteogenic transdifferentiation directly in vitro, and recombinant human BMP-9 was 
identified to be the most potent osteogenic inducer (Bondarava et al., 2017). Inspired 
by this, our following work focused on exploring growth factor delivery system to 
optimize osteogenic transdifferentiation for this novel tissue-based treatment.  
BMPs with osteogenic activity has attracted extensive interest as growth factors for 
enhanced bone construction. In particular, BMP-2, with the most effective osteogenic 
activity among BMPs, has been extensively used in non-union bone fractures, 
segmental  bone defects and spinal fusions (O. B. Betz et al., 2010; Mumcuoglu et al., 
2018), since the Food and Drug Administration (FDA) approved their clinical use for 
specific indications in 2002 (McKay, Peckham, & Badura, 2007).  
BMPs are considered to be promising stimulators for bone reconstruction, but their 
stimulation ability is still largely dependent upon the delivery vehicle. It has been 
reported that at an equivalent dose of BMP-2, sustained delivery exhibited enhanced 
osteogenesis as compared to short-time delivery (Jeon et al., 2008; Yang et al., 2010). 
The short biological half-life of recombinant BMP proteins and rapid loss through 
diffusion necessitate an improved delivery system that can regulate sustained release of 
BMP-2 (Jung et al., 2017). Applying large amounts of recombinant hBMP-2 may 
compensate for the fast degradation of protein but more often leads to unexpected side 
effects (Hajimiri, Shahverdi, Kamalinia, & Dinarvand, 2015).  
In order to achieve sustained delivery of BMPs and thereby a long-lasting bone 
regeneration stimulus, gene transfer technologies have been developed. It has been 
revealed that gene transduction with BMPs can significantly accelerate osteogenic 
differentiation and mineralization of stem cells in monolayer (Zachos, Shields, & 
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Bertone, 2010) or three-dimensional culture (Hao et al., 2010; Meinel et al., 2006). 
Meinel et al. compared the osteogenic performance of adenovirus encoding BMP-2 
(Ad.BMP-2) transduced MSCs and non-transduced MSCs but exposed to the same time 
concentration profile of BMP-2 generated by supplementing growth factor to culture 
medium, demonstrating that gene transduction resulted in higher levels of expression 
of osteogenic marker genes (Meinel et al., 2006).  However, the disadvantage of such 
cell-based gene enhanced tissue engineering approaches is that, as mentioned before, it 
requires an additional step of cell isolation and cultivation and therefore increasing time 
and cost (Aslan et al., 2006). Our strategy is to utilize gene activated soft tissue 
fragments as regenerative implants, which integrate stem cells, growth factors and 
scaffolds, the three key components of tissue engineering. 
Betz et al. have utilized muscle and subcutaneous fat tissue transduced with adenoviral 
BMP-2 vector to repair large bone defects in rats (Betz et al., 2009; Betz et al., 2010). 
The tissue grafts were brought in contact directly with the gene transferring vectors 
through transduction, leading to the genetically modification of cells on the surface of 
the tissue fragments. The so called “gene activated tissue grafts” represent biological 
regenerative implants providing growth factors and stem cells to the injury site.  
Subcutaneous fat tissue has led to a new focus towards bone regeneration as an 
abundant source of adipose derived stem cells. Numerous studies have shown the multi-
lineage differentiation capacity of ADSCs (Awad, Wickham, Leddy, Gimble, & Guilak, 
2004; Luzi et al., 2008; Zuk et al., 2002). More recently, the investigation into whether 
differentiation could be induced in the fat tissue fragments is drawing increasing 
attention. One In vitro study has revealed that under osteogenic stimulus, human fat 
tissue is capable to transdifferentiate into bone-like tissue (Bondarava et al., 2017). 
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Another  in vivo study applied Ad.BMP-2 activated fat tissue in order to heal critical-
size bone defects in rats (O. B. Betz et al., 2010).  
Skeletal muscle tissue represents another convenient source of stem cells, and thus 
holds great promise to serve as therapeutic autografts for bone regeneration. Various 
studies have applied muscle derived stem cells to repair or regenerate muscular disease, 
bone and cartilage defects as well as nerve injury (Lavasani et al., 2014; Matsumoto et 
al., 2009; Ota et al., 2011; Wright et al., 2002). In an expedited ex vivo gene therapy 
approach, muscle tissue fragments could be directly activated by gene transduction 
without prior cell isolation, leading to a rapid healing of large segmental bone defects 
(O. B. Betz et al., 2009).  
The fascia of skeletal muscle is a sheet of connective tissue consisting of fibroblasts. 
Although a growing number of studies have demonstrated that multipotent progenitor 
cells reside in fascia, few studies were performed investigating its regenerative capacity. 
It was recently reported that fascia derived stem cells possess chondrogenic potential 
(G. Li, Zheng, Meszaros, Vella, & Corsi, 2011). Wong et al. confirmed the multi-
lineage differentiation potential of fascia, including chondrogenic differentiation, 
osteogenic differentiation and adipogenic differentiation (Wong et al., 2015). As part 
of my thesis, I tried to answer the question whether the large number of fibroblasts in 
fascia could be effectively transduced by adenoviral vectors, making it a potential 
vehicle for growth factors delivery and thus enhancing osteoinduction of muscle tissue. 
Although gene activated fat tissue and muscle tissue’s promising capacity as 
regenerative implants for bone repair have been explored by several in vivo studies, to 
the best of our knowledge, few studies have investigated the hBMP-2 protein 
expression profile of genetically modified tissue fragments. It was also still unknown if 
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gene transduction or osteogenic differentiation of muscle tissue could be promoted by 
a fascia layer.  
Hence, the goal of the second publication was to evaluate and compare the potential of 
fat, muscle alone, and muscle with fascia tissue fragments to serve as BMP-2 delivering 
vehicles. In addition, the applied dosage of adenovirus BMP-2 vectors for transduction 
was optimized in order to achieve an ideal production of growth factor for future bone 
regeneration applications. 
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Osseous differentiation of 
human fat tissue grafts: From 
tissue engineering to tissue 
differentiation
Maryna Bondarava1, Chiara Cattaneo1, Bin Ren1, Wolfgang E. Thasler2, Volkmar Jansson1, 
Peter E. Müller1 & Oliver B. Betz1
Conventional bone tissue engineering approaches require isolation and in vitro propagation of 
autologous cells, followed by seeding on a variety of scaffolds. Those protracted procedures impede the 
clinical applications. Here we report the transdifferentiation of human fat tissue fragments retrieved 
from subcutaneous fat into tissue with bone characteristics in vitro without prior cell isolation and 
propagation. 3D collagen-I cultures of human fat tissue were cultivated either in growth medium or in 
osteogenic medium (OM) with or without addition of Bone Morphogenetic Proteins (BMPs) BMP-2,  
BMP-7 or BMP-9. Ca2+ depositions were observed after two weeks of osteogenic induction which 
visibly increased when either type of BMP was added. mRNA levels of alkaline phosphatase (ALP) 
and osteocalcin (OCN) increased when cultured in OM alone but addition of BMP-2, BMP-7 or BMP-9 
caused significantly higher expression levels of ALP and OCN. Immunofluorescent staining for OCN, 
osteopontin and sclerostin supported the observed real-time-PCR data. BMP-9 was the most effective 
osteogenic inducer in this system. Our findings reveal that tissue regeneration can be remarkably 
simplified by omitting prior cell isolation and propagation, therefore removing significant obstacles on 
the way to clinical applications of much needed regeneration treatments.
A growing aging population with an increased risk of bone fractures due to falls1, unfortunately often combined 
with impaired bone healing and even higher fracture risk due to osteoporosis2 and diabetes3,4, and, in addition, to 
the currently inevitable loosening of prosthetic implants over time5, urgently requires adequate bone regeneration 
strategies. The situation is exacerbated by a rising number of devastating traumatic war injuries for which often no 
other treatment option than amputation exists due to the extensive loss of bone and soft tissue6. Current treatment 
options are associated with high morbidity7–9 or deficient efficacy10. Mesenchymal stem cells (MSCs) in combina-
tion with various scaffolds are under intensive investigation and show promising achievements11–14. However, the 
involved procedure of cell isolation or separation is costly, leading to an estimated market worth 6.3 billion USD 
by 202015. Current tissue engineering strategies also involve subsequent in vitro propagation of the prior isolated 
or separated cells. These procedures add further substantial costs which is reflected in an estimated market worth 
14.8 billion USD by 201916. Extended cultivation time also holds a concerning higher risk of contamination and 
unwanted effects due to prolonged exposure to the cell culture media17. The cell propagation is currently done in 
external GMP-Facilities, which again adds costs, time and risks to the cell product. To avoid the issues afflicted 
with the use of an external GMP-Facility, the idea of a “GMP in a box”, in form of a fully automated bench-
top culture system within the primary-care facility of the patient seems very promising18. Not only would the 
use of tissue grafts instead of isolated and propagated cells clearly simplify such a system, therefore accelerating 
the availability, but because even when performed in the operating room and used autologously, cell separation is 
considered “more than minimally manipulated” by the FDA15, requiring a more rigorous approval process. Tissue 
grafts could therefore remove another obstacle on the road to a clinical application. Lastly, fat tissue grafts have 
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the potential to further the demand by surgeons for a same day, ex-vivo therapy19. For all those reasons above, it 
becomes obvious that technologies without the requirement of cell isolation and propagation would increase the 
chances to meet the need of the increasing number of patients for bone regeneration. Preclinical studies, showing 
that implantation of fat or muscle tissue fragments transduced with an adenoviral BMP-2 vector induces struc-
tural and functional healing of large segmental bone defects, were recently reported20–23. However, it remained 
unclear, whether the BMP-2 transduced tissue graft itself can undergo transdifferentiation into bone or if the graft 
rather serves as a delivery system for growth factors which stimulate and attract stem cells of the surrounding 
tissue21. If the latter would be the case, it would be advised to focus rather on drug delivery optimisation than 
cell therapies. Therefore, the aim of the present study was to investigate whether human fat tissue containing 
inhomogeneous cell populations is capable of transdifferentiation into tissue with bone characteristics. Adipose 
tissue harvest is associated with minimal donor site morbidity and it represents an especially appealing source of 
progenitor cells that can be used for the repair of bone21,24. A new culture system, introduced by Sonoda et al.25, 
represents adipose tissue fragments embedded in a three-dimensional collagen gel. This culture method was 
preferred in the present study not only because of the ability to easily entrap buoyant adipose tissue fragments, 
but also due to the support of a three-dimensional tissue structure mimicking an in vivo situation more closely 
and providing favourable conditions for cell differentiation. Bone morphogenetic proteins (BMPs) are known as 
bone forming growth factors. BMP-2 and BMP-7 have been shown to induce osteogenesis in vivo26–34, and both 
are available for clinical use35–37. Another promising growth factor inducing formation of bone is BMP-9. The 
superior potential of BMP-9 to induce osteogenic differentiation of MSCs was demonstrated both in vivo and 
in vitro38–46. However, no studies comparing the influence of BMP-2, BMP-7 and BMP-9 on human fat tissue 
fragments are available so far.
In this study, we used a modified, three-dimensional collagen I gel system to culture human subcutaneous 
fat tissue fragments in vitro. We evaluated whether cultivation with osteogenic supplements leads to tissue cal-
cification and expression of osteoblast specific protein markers. Additionally, the potential of three recombinant 
growth factors BMP-2, BMP-7 and BMP-9 to induce osteogenic transdifferentiation of fat tissue was explored 
and compared.
Results
3-Dimentional fat tissue culture system. After being embedded in collagen I gel, adipose tissue frag-
ments appeared under the phase contrast microscope as mature adipocytes attached to each other (Fig. 1A). 
After 5–7 days in culture, spindle-shaped cells were observed at the peripheral zones of the fragments migrating 
Figure 1. Phase contrast images of collagen-I fat cultures. (A) Freshly prepared culture. (B) Migration of 
spindle-shaped cells (arrows) out of the fat tissue in the collagen-I gel after 1 week of culture. (C) Migration of 
adipocytes (arrow) out of the fat tissue after 2 weeks of culture. (D) Spindle-shaped cells containing fat droplets 
(arrows) migrating into the collagen-I gel after 3 weeks of culture.
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into the collagen I gel (Fig. 1B). Furthermore, after the second week of culture, some adipocytes started to dis-
sociate from the tissue conglomerate. This could be observed exceedingly in samples cultured in normal growth 
medium (MN) (Fig. 1C). In addition to adipocytes and spindle-shaped cells, some preadipocyte-like cells with 
small fat droplets were observed in the late stages of the culture period of 4 weeks (Fig. 1D). Collagen-I gel was 
continuously shrinking during the whole period of incubation and losing its transparency under the osteogenic 
conditions. The migrating cells were spread throughout the collagen gel, partly covering the bottom surface of 
the 96-well plates.
Cell viability and proliferation. Cell viability and proliferation in the fat fragments was not only main-
tained for four weeks, but increased progressively over time in all experimental groups (Fig. 2). The highest 
WST-1 absorbance values, as an indicator of cell viability and proliferation, were observed in the osteogenic 
medium (MO) group: 0.23 ± 0.037 after 1 week, 0.64 ± 0.15 after 2 weeks, and 2.19 ± 0.36 after 4 weeks of incu-
bation. Less increase in absorbance was observed in cultures treated with normal media (MN): 0.29 ± 0.06 after 
1 week, 0.44 ± 0.12 after 2 weeks, and 1.49 ± 0.08 after 4 weeks of incubation. However, no significant difference 
was detected between the MO and MN groups. In contrast, significant lower absorbance values in compari-
son to MN were detected in all groups treated with BMPs after 4 weeks of incubation: 0.23 ± 0.04; 0.50 ± 0.12; 
0.72 ± 0.25 (p ≤ 0.05) after 1, 2 and 4 weeks respectively in the MO-BMP-2 group; 0.27 ± 0.04; 0.61 ± 0.18; 
0.76 ± 0.24 (p ≤ 0.05) after 1, 2 and 4 weeks respectively in the MO-BMP-7 group; 0.30 ± 0.07; 0.46 ± 0.09; 
0.62 ± 0.14 (p ≤ 0.01) after 1, 2 and 4 weeks respectively in the MO-BMP-9 group, indicating a significant lower 
proliferation rate in the BMP receiving groups. No significant difference between the BMP-groups was observed.
Histology. After one week of incubation, none of the five groups displayed calcium depositions. 
(Figs 3A,D,G,J,M and 4A,D,G,J,M). After the second week of incubation, the samples treated with MN showed a 
higher number of cell nuclei located between the adipocytes than compared to cultures under osteogenic condi-
tions. This suggests a higher proliferation of stromal cells in the MN group. Samples treated with MO displayed 
some regions of calcification located in the stromal cell fraction between adipocytes. The fat grafts of the BMP-2, 
-7 and -9 groups displayed a remarkable increase in extracellular calcification, as confirmed by alizarin red S as 
well as by von Kossa staining (Figs 3H,I,K,L,N,O and 4H,I,K,L,N,O). After the fourth week of incubation the 
proliferation of the stromal cells in the MN group increased even further replacing adipocytes almost completely. 
The samples treated with MO and MO + BMPs demonstrated a strong overall tissue calcification, which included 
the adjacent collagen I gel. There was no significant difference in the calcification rate observed between MO and 
MO + BMP-2, -7 or -9 experimental groups after the 4th week of incubation.
Real-time quantitative PCR (RT-PCR). Osteogenic differentiation of the 3D cultures was confirmed by 
quantitative real-time PCR measuring the expression of the early bone marker ALP and the later bone marker 
OCN mRNA. The expression of these markers in native fat tissue of each patient served as a baseline (calibrator). 
The mRNA expression of the early bone marker ALP after one week of culture was significantly (p ≤ 0.001) higher 
in samples treated with MO plus BMP-2 (2.87 ± 0.46), BMP-7 (2.78 ± 0.56) and BMP-9 (6.90 ± 2.00) compared 
to samples treated with MN (0.66 ± 0.15) or MO (0.80 ± 0.19, p ≤ 0.01 or p ≤ 0.001). The ALP-expression for MO 
plus BMP-9 was significantly higher than for all other groups (Fig. 5a). After the second week of culture the level 
of ALP in the MO + BMP-9 group was still significantly higher (4.75 ± 0.82, p ≤ 0.01) than in the other groups: 
MN (0.81 ± 0.27), MO (1.08 ± 0.28), MO + BMP-2 (1.56 ± 0.31), MO + BMP-7 (0.55 ± 0.07). However, after 
the fourth week of incubation the highest level of ALP expression was observed in the MO group (2.16 ± 0.39, 
p ≤ 0.001). The groups MO + BMP-2, MO + BMP-7 and MO + BMP-9 showed significantly higher ALP expres-
sion values (0.84 ± 0.12; 1.35 ± 0.31; 1.64 ± 0.32 respectively, p ≤ 0.05 or p ≤ 0.001) compared to the MN group 
(0.48 ± 0.14) as well (Fig. 5a).
OCN mRNA expression after the first week of culture was significantly higher in the samples treated with 
MO containing BMP-2 (0.30 ± 0.05), BMP-7 (0.40 ± 0.09) or BMP-9 (0.93 ± 0.29) than in samples treated with 
MN (0.14 ± 0.03, p ≤ 0.05) or MO (0.12 ± 0.02, p ≤ 0.01 or p ≤ 0.001) (Fig. 5b). After the second week of culture 
the level of OCN expression was significantly higher in the samples treated with MO (0.21 ± 0.03, p ≤ 0.05), 
MO + BMP-2 (0.43 ± 0.10, p ≤ 0.001), MO + BMP-7 (0.30 ± 0.06, p ≤ 0.01) and MO + BMP-9 (0.29 ± 0.04, 
p ≤ 0.001) compared to the samples treated with MN (0.11 ± 0.02). After the fourth week of incubation the 
Figure 2. WST-1 measurement of fat tissue cultures under different differentiation culture conditions. 
Values given represent means ± SE, n = 6–7. The level of significance was set as * for p < 0.05, ** for p < 0.01 and 
*** for p < 0.001.
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OCN mRNA was significantly overexpressed in the groups MO, MO + BMP-2, MO + BMP-7 and MO + BMP-9 
(0.60 ± 0.03, p ≤ 0.001; 0.56 ± 0.13, p ≤ 0.001; 0.47 ± 0.12, p ≤ 0.01 and 0.90 ± 0.28, p ≤ 0.001 respectively) com-
pared to to the MN group (0.14 ± 0.03) (Fig. 5b).
Immunofluorescence. Immunofluorescent staining of native fat tissue fragments for the bone markers 
osteocalcin (OCN) and osteopontin (OPN) showed that these proteins were endogenously expressed at very 
low levels in the adjacent blood vessels and in some niches of the stromal cells within fat tissue, but not in the 
adipocytes (Fig. 6A,B). In contrast, sclerostin could not be detected in native fat samples (Fig. 6C). After 4 weeks 
of culture in MN, the bone markers OCN and OPN could still be detected intracellular, although at minimal 
levels, mostly localized in the cell nuclei (Fig. 6D,E). Expression of sclerostin was not observed in MN cultures 
(Fig. 6C,F). Samples treated with MO displayed a low fluorescence signal for OCN and OPN (Fig. 6G,H) and a 
positive signal for sclerostin (Fig. 6I). All the samples treated with MO and supplemented with BMPs (BMP-2, 
BMP-7, BMP-9) showed strong fluorescence signals for OCN, OPN and sclerostin (Fig. 6J–R). There was no 
apparent difference observed concerning the expression of OCN and OPN between the three different BMPs. 
Sclerostin expression appeared to be higher in samples treated with MO + BMP-7 and MO + BMP-9 compared 
Figure 3. Histological sections of fat cultures after 1, 2 or 4 weeks under various differentiation conditions. 
Sections were stained with Alizarin red S: 1 week: (A) MN, (D) MO, (G) MO + BMP-2, (J) MO + BMP-7,  
(M) MO + BMP-9; 2 weeks: (B) MN, (E) MO, (H) MO + BMP-2, (K) MO + BMP-7, (N) MO + BMP-9; and 4 
weeks of incubation: (C) MN, (F) MO, (I) MO + BMP-2, (L) MO + BMP-7, (O) MO + BMP-9. Scale bar = 200 μm.
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to MO + BMP-2 (Fig. 6L,O,R). Furthermore, fluorescence signals from OCN, OPN and sclerostin in samples 
treated with MO + BMPs were observed not only intracellular, but also extracellular and to some extend in the 
surrounding collagen I matrix.
Discussion
In this study we employed a 3D fat tissue culture system established by Sonoda et al.25 with minor adaptations. 
Despite our adaptations, most of the vitality and histological data were in line with the results found by Sonoda 
et al.25. The fat tissue cultures in collagen I gel did not only retain their viability but rather displayed increasing 
vitality parameters over 4 weeks. The migration and proliferation of spindle-shaped cells were observed at the 
periphery of the fat tissue fragments. Cells of the same phenotype were shown by Sonoda et al. (Fig. 1B) to 
express CD 44 and CD 105 – the surface markers of mesenchymal stem cells25. Capable of migration and prolif-
eration, these cells might contribute to the osteogenic differentiation described in the present study. The dissoci-
ation of adipocytes at the late phase of the tissue culture was not shown before25. A possible reason could be the 
human origin of the tissue as opposed to the rat origin used by Sonoda and the difference in culture conditions. 
Only very few spindle-shaped cells containing lipid droplets (Fig. 1D) were observed in the cultures, making it 
Figure 4. Histological sections of fat cultures after 1, 2 or 4 weeks under various differentiation conditions. 
Sections were stained with von Kossa: 1 week: (A) MN, (D) MO, (G) MO + BMP-2, (J) MO + BMP-7,  
(M) MO + BMP-9; 2 weeks: (B) MN, (E) MO, (H) MO + BMP-2, (K) MO + BMP-7, (N) MO + BMP-9; and 4 
weeks of incubation: (C) MN, (F) MO, (I) MO + BMP-2, (L) MO + BMP-7, (O) MO + BMP-9. Scale bar = 200 μm.
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highly unlikely, that these cells are exclusively responsible for the osteogenic differentiation of the fat grafts. This 
observation rather suggests the presence of preadipocytes or dedifferentiated adipocytes within the fat tissue. 
Moreover, the vitality of the 3D cultures was continuously increasing during the first two weeks of culture with no 
significant difference between the experimental groups (Fig. 2). However, after 4 weeks of incubation the vitality 
of groups containing recombinant BMPs (BMP-2, -7 and -9) was significantly lower than in MN and MO groups. 
Addition of osteogenic growth factors to the cultures caused an accelerated differentiation rate but also a decrease 
of the proliferation rate. This was to be expected as cell differentiation has long been recognised as an opposing 
process to cell proliferation47.
Accumulation of calcium under osteogenic conditions was observed mostly among mature adipocytes at the 
sites of stromal cell localisation, or in the niches of progenitor cells (Figs 3 and 4). Presumably, only these cells pro-
duce a sufficient number of progenitors that can respond to osteogenic stimuli and differentiate into the respective 
lineage. Moreover, calcification in samples containing BMPs was observed in the collagen I gel adjacent to the fat 
tissues, suggesting the contribution of migrated cells to the overall calcification (Figs 3L,O and 4I).
Calcium accumulation during osteogenic differentiation was already described in several studies on 
adipose-derived stem cells cultured in monolayer24,48 or in 3D cultures49,50. To the best of our knowledge, this 
reported study demonstrates for the first time, osteogenic differentiation, including calcification of 3D fat tissue 
cultures of human origin in vitro. Although, Betz et al.20 have demonstrated that BMP-2 gene-activated fat tissue 
is an osteoregenerative material that has the ability to repair critical-sized bone defects in rats21, it was still unclear, 
whether the gene-activated tissues expressing BMP-2 transform into bone or solely serve as a delivery system 
for BMP-2 stimulating and attracting stem cells of the surrounding tissue. The presented data substantiates our 
hypothesis that fat tissue has the potential for the transition into bone tissue.
The RT-PCR data reveals increased mRNA expression of the bone markers ALP and OCN under osteogenic 
culture conditions. Moreover, the addition of BMP-2, -7 and -9 seems to induce osteogenesis in the fat tissue 
earlier and more intensively than osteogenic medium alone. These data were supported by the immunofluores-
cent staining for OCN, OPN and Scl. Furthermore, Scl appears to be the most specific osteogenic marker in this 
system, as it was only detectable after osteogenic stimulation but not in the native or in MN cultured tissue. The 
presented data support the hypothesis, that osteogenesis can be induced in human fat tissue without isolation 
of progenitor cells. The presence of mesenchymal stem cells and their osteogenic potential were confirmed for 
different types of adipose tissue by numerous studies48,50,51. However, no data was reported so far on fat tissue 
transdifferentiation in vitro. Limited in vivo data reporting transdifferentiation between white and brown types 
of fat cells52 as well as fat-epithelial cell differentiation53,54 was reported. Moreover, Gao et al.55 described recent 
Figure 5. Quantitative RT-PCR analysis of 3D fat cultures incubated under different differentiation 
conditions. Expression of mRNA for ALP (a) and OCN (b) normalized to mRNA levels for GAPDH. Values 
given represent means ± SE, n = 10–11. The level of significance was set as * for p < 0.05, ** for p < 0.01 and  
***for p < 0.001.
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insights in studying transdifferentiation of bone and fat related to bone metabolism. Subsequent research revealed 
the capacity of subcutaneous preadipocytes to differentiate into osteoblasts56. Other studies reported, that mature 
lipid-filled adipocytes transdifferentiated into mature osteoblasts through the preadipocytic stage with increased 
cell proliferation57,58. Also, it was discovered that single adipocytes are capable to dedifferentiate into cells with 
fibroblast-like morphology and subsequently turn into osteoblasts or adipocytes under respective stimulation58,59.
The osteogenic BMPs hold great promise for regenerative medicine60. Our results have demonstrated that 
BMP-2, -7 and -9 represent osteogenic activities and enhance osteogenic differentiation of human fat tissue 
in vitro at the mRNA and protein level. Moreover, BMP-9 seems to be a more potent osteogenic inducer for cells 
within fat tissue than BMP-2 or -7. This observation is in line with the previous studies conducting comprehen-
sive analysis of different types of human BMPs39,41,61,62. By using recombinant adenoviruses in order to facili-
tate the expression of 14 different BMPs, Luu et al., 2006 have demonstrated that, besides BMP-2 and BMP-7, 
BMP-6 and BMP-9 show the highest osteogenic activity in vitro as well as in vivo39. Li et al., 2003 have reported 
that BMP-9 displays the greatest osteogenic potential in vitro and in Sprague-Dawley rats62. Furthermore, Kang 
et al.41 suggested that high osteogenic activity of BMP-9 may be explained by transduction of a distinct osteogenic 
signalling pathway that is completely different from that of BMP-2, BMP-6 and BMP-741. One reason for the 
osteogenic potency of BMP-9 is most likely the fact, that it cannot be inhibited by noggin, an effective inhibitor 
of BMP-2 and -763,64. This would also explain why BMP-9 is involved in traumatic, heterotopic ossification where 
small amounts of BMP-9 can induce ossification of soft tissue in humans65.
In conclusion, we have demonstrated for the first time that human fat tissue is able to undergo osteogenic 
transdifferentiation under 3D culture conditions in vitro, although it remains unclear which compartments of the 
heterogenic cell population within the fat tissue are responsible for the differentiation process. We furthermore 
evaluated the osteogenic potential of human recombinant BMP-2, -7 and -9 in this system. Here, BMP-9 was 
identified to be the most potent osteogenic inducer. Our results suggest that human subcutaneous fat tissue may 
represent a regenerative material, which could be applied without cell isolation in expedited bone regeneration 
strategies21,23. Future investigations should be directed toward understanding the cellular and molecular mecha-
nisms of fat tissue transdifferentiation in vitro and in vivo and also toward the role of BMPs in this context with a 
potential focus on BMP-9.
At the clinical research front, the combinations of different BMPs and other growth factors should be evaluated 
for synergic osteogenic activity. In addition, alternative and safe BMP- delivery approaches need to be developed 
to enable efficient, safe and cost effective therapies for bone regenerative medicine.
Figure 6. Histological sections of fat cultures after 4 weeks under various differentiation conditions. 
Immunofluorescence for OCN, OPN and Scl is shown in green. Control (Ctrl) samples (A–C) represent the 
untreated fat fragments. Samples treated with MN are shown in the images (D–F); MO at (G–I); MO + BMP-2 
in (J–L); MO + BMP-7 in (M–O); MO + BMP-9 in (P–R). Nuclei of cells (blue) are shown in the corresponding 
images (A’–R’). Scale bar = 50 μ m.
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Methods
Tissue Harvest and 3-Dimentional Culture System. The tissues and data used in this study were 
provided by the Biobank (http://www.klinikum.uni-muenchen.de/Chirurgische-Klinik-und-Poliklinik-
Grosshadern/de/0800-gewebebank/index.html) located in the Hospital of the University of Munich, which oper-
ates in accordance with the European Union-compliant ethical and legal framework of the Human Tissue and 
Cell Research (HTCR) Foundation (http://www.htcr.org). The process of tissue collection included obtaining 
written informed consent from all tissue donors. The experimental procedures were performed within the frame-
work of the HTCR. This framework has also been approved by the ethics commission of the Faculty of Medicine 
in the University of Munich and the Bavarian State Medical Association66.
The subcutaneous fat tissue was obtained from 5 patients of different sex (age from 31–80, BMI 29–52). After 
rinsing with PBS containing 120 IU/ml penicillin/streptomycin and 0,375 μ g/ml amphotericin B (Biochrom, 
Germany), the adipose tissue was punched with a biopsy punch to create fragments of approximately 2 mm in 
diameter. Each fragment was then embedded in 50 μ l type I collagen gel solution (3D Collagen Culture Kit, Merck 
Millipore, Germany), which was prepared according to the manufacturer’s protocol, and placed in a 96-well tissue 
culture plate. After polymerization of the collagen, the cultures were covered either with normal, maintaining 
media (MN) (Ham’s F12/DMEM (Biochrom), 10% FCS (Sigma), 60 IU/ml penicillin/streptomycin) or osteogenic 
media (MO) (MN + 50 μ M L-ascorbic acid 2-phosphate, 10 mM β -glycerophosphate, 10 nM dexamethasone) 
alone or with addition of one of the growth factors from the BMP superfamily (100 ng/ml): rhBMP-2, rhBMP-7 
(Biomol, Germany) or rhBMP-9 (Bio-Rad, Germany). The media were changed every second day. Microscopic 
observations were performed using Axiovert 40 CFL equipped with AxioCam ERc 5 s (Carl Zeiss, Germany) after 
one day and after 1, 2 and 4 weeks of culture. Images were taken using AxioVision SE64 Rel. 4.9 software (Carl 
Zeiss, Germany). 6 cultures per one experimental group and time point were prepared and evaluated from each 
patient (90 cultures per patient).
Cell viability. Cell viability of the 3D fat cultures was determined using a water-soluble tetrasolium-1 (WST-1) 
reagent (Roche, Germany). The assay was performed after 24 hours and subsequently after 1, 2 and 4 weeks of 
culture. Briefly, the culture medium was discarded. The fresh growth medium was mixed with WST-1 at 10:1 
(v/v), added to the wells with 3D cultures or to the empty wells (blanks) and incubated for 2 hours at 37 °C in 5% 
CO2. After the incubation, 100 μ l of medium-WST-1 mixture was transferred to a 96-well culture plate and the 
absorbance was read at 450 nm using Synergy HT microplate reader and Gen 5 2.03 software (BioTek, Germany). 
The assay was repeated 7 times in the independent cultures.
Histology. Fresh fat tissue samples or 3D fat cultures were embedded in Tissue-Tek O.C.T.TM Compound 
(Sakura, Germany) and frozen immediately in liquid nitrogen. Tissue sections of 14 μ m were cut by the cryomi-
crotome (CM 3050, Leica, Germany), transferred onto SuperfrostTM Plus microscope slides (Thermo Scientific, 
USA) and air-dried. All samples were prepared in triplets.
Alizarin red S staining. Deposition of calcium in the tissue was evaluated by means of Alizarin red S staining. 
The sections were fixed with 4% Paraformaldehyde (PFA) for 15 minutes at room temperature (RT) and rinsed 
with distilled water. They were then stained with freshly prepared 40 mM alizarin red S (Sigma) solution, pH 4,1 
for 10 minutes at RT and washed in PBS. The samples were dehydrated in 100% Ethanol, cleared in Rothistol 
(Roth, Germany) and mounted with DPX (Merck).
Von Kossa staining. Slides fixed with PFA 4% and washed in distilled water were stained in 5% silver nitrate 
solution (Sigma) in the darkness for 5 minutes. They were then washed with distilled water and treated with 1% 
pyrogallic acid (Sigma) for 5 minutes. After washing and fixing with 5% NaOH for 4 minutes, the samples were 
stained with May-Grünwald stain (Sigma) for 10 minutes, dehydrated with 100% Ethanol, cleared with Rothistol 
and mounted with DPX.
RNA isolation and quantitative real-time PCR. The expression of ALP and OCN were analysed in 
combination with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) after 1, 2 and 4 weeks of culture. 
Total mRNA was extracted using QIAzol Lysis Reagent (Qiagen, Gemany) according to manufacturer’s protocol. 
Briefly, the cultures were frozen in liquid N2 and homogenised using the Mikro-Dismembrator S (Sartorius 
Stedim Biotech, Germany). Subsequently, 1 ml QIAzol Lysis Reagent was added to the homogenate, resuspended 
and mixed with chloroform. After centrifugation, the upper aqueous phase was transferred to a new tube and 
mixed with isopropanol. The mRNA containing pellet was washed twice with 75% Ethanol, air-dried and redis-
solved in RNase-free water. After the incubation at 37 °C for 20 minutes RNA concentration and purity were 
assessed with the spectrophotometer (NanoDropTM Lite, Thermo Scientific).
cDNA synthesis was performed for 15 minutes at 42 °C using Thermocycler (T100, Bio-Rad, Germany) in a 
reaction mixture containing 300 ng total RNA, buffers, Quantiscript reverse transcriptase and RT primer mix 
from QuantiTect Reverse Transcription-Kit (Qiagen, Germany) adjusted with RNase-free water to a total volume 
of 20 μ l.
Amplification of the cDNA products was performed using the FastStart Essential DNA Green Master 
(Roche Applied Science, Germany) and the Light Cycler 96 (Roche, Germany). The reaction mixture 
contained 2,5 μ l cDNA, 300 ng primer, 5 μ l FastStart Essential DNA Green Master and RNase free water 
to a final volume of 10 μ l. Primer sequences: GAPDH forward TGCACCACCAACTGCTTAGC, reverse 
GGCATGGACTGTGGTCATGAG (annealing temperature 60 °C); ALP forward TCAAGGGTCAGCTCC 
ACCACA, reverse ATTGGCCTTCACCCCACACA (60 °C); OCN forward CCCAGGCGCTACCTGTATCAA, 
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reverse CTGGAGAGGAGCAGAACTGG (64 °C). Primers were obtained from Metabion (Germany). 
Amplification was performed in triplicates in 96 well plates (Roche, Germany). Relative gene expression between 
samples was calculated using the 2−ΔΔCt method, considering GAPDH as a housekeeping gene and untreated fat 
tissue as a calibrator.
Immunofluorescent staining. The tissue sections were fixed with 4% PFA and washed in PBS with 0,1% Brij 
(Sigma). Non-specific binding sites were blocked by 5% bovine serum albumin (BSA) for 30 minutes. Thereafter, 
primary antibody was added and incubated overnight. All primary antibodies (OCN, OPN, Scl) were mouse 
monoclonal IgGs from R&D Systems (Germany) used in concentrations: 25 μ g/ml (OCN, OPN) and 10 μ g/ml 
Scl. For negative controls, the first antibody was omitted. After washing off unbound antibody and permeabili-
zation with 0,1% Triton X-100 solution (Sigma) in PBS the secondary antibody goat antimouse IgG conjugated 
with Alexa Fluor 488 (Invitrogen, Germany) in the dilution 1:400 was added for 30 minutes, then intensively 
washed. Finally, the nuclei of cells were stained with Hoechst 33342 (Life Technologies, Germany). The slides 
were mounted with Fluoromount W (Serva Electrophoresis, Germany), air-dried and stored in darkness at 4 °C.
Microscopy was performed with the Zeiss Axioskop 40 equipped with appropriate filter sets and AxioCam 
MRc 5. Images were obtained with an Axio Vision, Rel. 4.9 software (Carl Zeiss, Germany).
Statistical data analysis. Data analysis was performed with Microsoft Excel 2010 and Prism 5.02 software 
for Windows. Values were presented as mean ± standard error. The Mann-Whitney U-test was used to determine 
differences between compared groups as a Gaussian distribution could not be assumed. The level of significance 
was indicated by * for p < 0.05, ** for p < 0.01 and *** for p < 0.001.
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J Tissue Eng Regen Med. 2017;1–10.Abstract
Previously, we have presented an expedited strategy for sustained delivery of bone morphoge-
netic protein‐2 (BMP‐2) to bone lesions based on the implantation of gene‐activated fat and
muscle fragments. The aim of the present in vitro experiments was to evaluate the potential of
muscle with fascia as a BMP‐2 delivering osteo‐regenerative implant in comparison to fat tissue
and muscle alone. Subcutaneous fat, muscle, and muscle with fascia were harvested from Fischer
344 rats. The tissues were cut into small pieces and cultured for up to 90 days after direct
transduction with adenoviral BMP‐2 or green fluorescence protein vectors. Different vector
doses were applied, and proliferation, long‐term BMP‐2 production, and osteogenic differentia-
tion of the 3 different tissues were investigated in vitro. Muscle with fascia produced the largest
amounts of BMP‐2. Expression of the transgene was detected for up to 90 days. Proliferation
was reduced with increased vector doses. Muscle with fascia showed a higher potential for
osteogenic differentiation than fat, but it was not improved as compared to muscle alone. A dose
of 4 × 108 plaque forming units of the adenoviral BMP‐2 vector appeared to be the optimal dose
for transduction of muscle with fascia. Because muscle with fascia produced higher amounts of
BMP‐2 as compared to muscle alone or fat tissue grafts, showing a high potential for osteogenic
differentiation, it might represent an improved osteo‐regenerative implant facilitating
endogenous repair. Future studies should investigate the effect of muscle with fascia transduced
with 4 × 108 plaque forming units on bone healing in vivo.
KEYWORDS
bone regeneration, fascia, fat tissue, gene therapy, muscle tissue, osteogenic differentiation1 | INTRODUCTION
Delayed fracture healing, non‐unions, and large osseous defects remain
great clinical challenges for surgeons around theworld. In an ageing pop-
ulation, the demand for effective treatment options for such problems
will dramatically increase in the near future (Schacter & Leslie, 2017).g the bone morhogenetic protein g
osome; BMP, bone morphogenet
DH, gadolinium phosphate dehy
pfu, plaque forming units; WST‐1
wileyonlinelibrary.com/journ
24The biological stimulation of bone growth by bone morphogenetic
proteins (BMPs) holds great promise and has been performed clinically
(Alt et al., 2015). However, delivery of such osteogenic molecules
needs to be improved because of their short biological half‐life
(Jung et al., 2017). In order to achieve sustained delivery of BMPs
and thereby a long lasting bone regeneration stimulus, gene transferene; Ad.GFP, adenoviral vector carrying the green fluorescent protein gene; ALP,
ic protein; CMV, cytomegalovirus; DMEM, Dulbecco's modified eagles medium;
drogenase; GFP, green fluorescence protein; HEK, human embryonic kidney;
, water‐soluble tetrazolium‐1
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2 REN ET AL.technologies have been developed. A drawback of such cell‐based
gene‐enhanced tissue engineering approaches is that they require
the isolation and expansion of autologous progenitor cells in an
external good manufacturing practice‐facility making them costly
and time‐consuming (Aslan et al., 2006). Another issue is the
need for two separate surgical procedures, which increases costs
of the approach and risks for the patient. The complexity of
such methods impedes the translation from bench to bedside
(Betz, Betz, Harris, Vrahas, & Evans, 2008). Therefore, the goal must
be the development of simple same day, ex vivo gene therapies,
which can be performed during a single surgical procedure (Virk
et al., 2011).
The use of tissue grafts instead of isolated cells enables us to
develop ex vivo gene transfer protocols that are better suited to
clinical application. Betz et al. have utilized muscle and subcutaneous
fat tissue transduced with an adenoviral BMP‐2 vector to repair large
bone defects in rats (Betz et al., 2009; Betz et al., 2010). The tissue
grafts were directly contacted with the gene transfer vector leading
to the genetically modification of cells on the surface of the tissue
fragments. The so called “gene‐activated tissue grafts” represent
biological, defect‐filling implants delivering growth factor and stem
cells to the bone lesion. The stem cells within the muscle and adipose
tissue grafts reside in their natural niches, which might support their
proper function and capacity for differentiation.
Fat tissue got increasingly popular for bone tissue engineering
purposes as it is easy to harvest in large quantities and contains
progenitor cells with a proven osteogenic differentiation capacity
(Tevlin et al., 2016). Adipose tissue fragments, genetically modified to
overexpress BMP‐2, have been successfully employed in a rat
critical‐size bone defect model (Betz et al., 2010). The implantation
of BMP‐2 gene‐activated fat led to fast and robust structural and
functional healing of femoral defects. Moreover, in recent work, it
could be demonstrated that human fat tissue can transdifferentiate
into bone‐like tissue (Bondarava et al., 2017).
Muscle is another candidate tissue that can serve as an osteo‐
regenerative implant. Skeletal muscle possesses intrinsic scaffolding
properties, and its harvest is associated with low donor site morbidity
(Ahmad, Akhtar, Rashidi, & Khurram, 2013). Huard and colleagues have
shown that muscle tissue hosts stem cells that can differentiate into
the osteogenic lineage in vitro and in vivo (Gao et al., 2013; Wright
et al., 2002). Recent studies exploring the potential of gene‐activated
muscle tissue grafts for bone repair could demonstrate that BMP‐2
producing muscle implants rapidly heal large bone defects in rats
(Betz et al., 2009). Interestingly, implantation of genetically modified
muscle led to similar biomechanical stability and bone volume as
compared to bone grafting (Betz et al., 2013).
The fascia of skeletal muscle consists of fibrous connective tissue
containing fibroblasts. Only very little is known about the potential of
fascia cells to regenerate other tissues. Recent work characterized
fascia‐derived cells in terms of their surface marker profile, prolifera-
tion rate, and chondrogenic potential (Li et al., 2011). The findings of
this study suggest that the nonmyogenic cells of fascia have a strong
chondrogenic potential and may contribute to ectopic bone formation
in muscle via endochondral ossification. Our hypothesis was that fascia
contains a larger number of cells on the surface as compared to muscle25and fat resulting in improved transduction efficiencies and larger
amounts of osteogenic molecules delivered to a site of bone injury.
Moreover, an advantage for clinical use may be that fascia has
favourable physical properties allowing a more stable fixation within
a lesion, for example, by suturing.
Hence, the aim of the present in vitro experiment was to evaluate
the potential of muscle with fascia to serve as a BMP‐2 delivering
osteo‐regenerative implant in comparison to muscle alone and fat
tissue. In addition, the optimal dose of an adenoviral BMP‐2 vector
for transduction of muscle with fascia was investigated.2 | MATERIALS AND METHODS
2.1 | Vector production
Two different, first generation, serotype 5, E1, E3 deleted adenoviral
vectors were used in this study: Ad.GFP (green fluorescent protein)
and Ad.BMP‐2 (bone morphogenetic protein‐2). The vectors were
constructed as reported previously (Betz et al., 2013) (Sirion Biotech
GmbH, Martinsried, Germany). In summary, the transgene (GFP or
BMP‐2) coding regions were amplified by PCR and subcloned into
the shuttle vector pO6‐A5‐CMV. The CMV‐transgene portion of
pO6A5‐CMV‐transgene was transferred in a BAC vector containing
the genome of an Ad5‐based E1/E3 deleted vector. Finally,
HEK‐293 cells were transfected with the adenoviral DNA, and
amplified viral vector particles were chromatographically purified
with ViraBind™ Adenovirus Purification Kit (Cell Biolabs Inc., San
Diego, USA).2.2 | Harvest of tissues, transduction, and culture
system
Subcutaneous fat, muscle tissue, and muscle with fascia were har-
vested from the hind limbs of two donor animals. Small fragments of
each tissue type were created using 4‐mm dermal biopsy punches
(pfm medical, Cologne, Germany). The round tissue pieces were then
placed in 24‐well plates and transduced with the adenoviral vectors
carrying the BMP‐2 or GFP cDNA using various concentrations rang-
ing from 1 × 107 to 1 × 108 pfu for fat and muscle, and 1 × 107 to
1 × 109 pfu for muscle with fascia. Aliquots of 10 μl of the adenoviral
vectors diluted in Dulbeccos's modified Eagle's medium (DMEM;
BiochromeAG, Berlin, Germany) were added to the surface of the
tissue fragments. Subsequently, the tissues were stored in an
incubator (37 °C, 5% CO2) for 1 hr. Four tissue fragments per well
were cultured in a 24‐well plate with 1 ml of DMEM (BiochromeAG,
Berlin, Germany) for up to 90 days. Culture medium was changed
every third day.2.3 | Imaging of GFP‐transduced tissue fragments
under laser‐scanning confocal microscopy
Forty‐eight hours after transduction, adenoviral GFP‐transduced
tissue fragments were rinsed with phosphate buffered saline and
then placed on a histological glass. The samples were imaged using
an inverted laser‐scanning confocal microscopy system (LSM 880;
REN ET AL. 3Zeiss, Jena, Germany) with a 5× air objective (Zeiss, 0.25 NA,
WD = 12.5 mm).
2.4 | Quantitative analysis of adenoviral GFP‐
transduction efficiency
Quantitative analysis of adenoviral GFP‐transduction efficiency was
performed using the Image J software v.1.6 (NIH). The area occupied
by GFP‐positive cells and the total area of the tissue disc were
established. Values were expressed as a mean percentage of GFP‐pos-
itive cells occupied area within the total area of tissue discs.
2.5 | Proliferation determined by water‐soluble
tetrazolium‐1 (WST‐1) assay
The ability of the cells of the tissues to proliferate was evaluated apply-
ing a WST‐1 reagent (Roche, Mannheim, Germany) after 1, 2, 3, and
4 weeks. To perform the assay, the culture medium was discarded,
and fresh medium was mixed with WST‐1 at a ratio of 10:1(v/v).
The tissue samples were then incubated together with the medium‐
WST‐1 mixture for 2 hr at 37 °C in 5% CO2. Subsequently, 100 μl of
the mixture was transferred to a 96‐well culture plate reading the
absorbance at 450 nm with a Synergy HT microplate reader using
the Gen 5 2.03 software (BioTek, Bad Friedrichshall, Germany).
2.6 | BMP‐2 production measured by an enzyme‐
linked immunosorbent assay (ELISA)
The amounts of BMP‐2 that were produced by the three different
tissue types were determined using ELISA (Quantikine, BMP‐2 Immu-
noassay, R&D Systems, Wiesbaden, Germany). Supernatants of tissue
cultures were harvested every third day and collected over 30 days
for fat and muscle and for up to 90 days for muscle with fascia.
BMP‐2 content in supernatants was measured according to the
manufacturer's instructions. Absorbance was read using a Synergy
HT microplate reader and the Gen 5 2.03 software (BioTek, Bad
Friedrichshall, Germany).
2.7 | Quantitative real‐time PCR analysis of
osteogenic differentiation
Gene expression of alkaline phosphatase (ALP) and osteocalcin (OCN)
was analysed by quantitative real‐time PCR after 2 and 4 weeks.
Tissues were frozen in liquid nitrogen and homogenized with a
Mikro‐Dismembrator S (Sartorius, Goettingen, Germany). The homog-
enate was then resuspended in 1 ml of QIAzol Lysis Reagent (Qiagen,
Gemany), mixed with chloroform and centrifuged. Then the upper
aqueous phase was collected and mixed with isopropanol. After centri-
fugation, total RNA pellet was rinsed with 75% ethanol, air‐dried and
re‐dissolved in RNase‐free water. The concentration and purity of total
RNA were determined with a spectrophotometer (NanoDropTM Lite,
Thermo Scientific, Waltham, USA). A thermocycler (T100, Bio‐Rad,
Germany) was used for cDNA synthesis (15 min at 42 °C). The reaction
mixture contained 300 ng of total RNA, Quantiscript reverse transcrip-
tase and RT primer mix from QuantiTect Reverse Transcription‐Kit
(Qiagen, Hilden, Germany) and buffers, diluted with RNase‐free water26to a total volume of 20 μl. The FastStart Essential DNA Green Master
(Roche Diagnostics, Mannheim, Germany) and the Light Cycler 96
(Roche Diagnostics, Mannheim, Germany) were used for amplification
of cDNA. The following reaction mixture at a final volume of 10 μl was
used: 2.5 μl of cDNA, 0.5 μM of primer, 5 μl FastStart Essential DNA
Green Master, and 2 μl RNase free water. The primers were purchased
from Qiagen (Hilden, Germany). PCR reaction conditions were 10‐min
preincubation at 95 °C, 10‐s denaturation at 95 °C, followed by 10‐s
annealing at 60 °C and 15‐s extension at 72 °C for 40 cycles.
Amplification was performed in triplicates. The 2−ΔΔCt method was
applied to calculate the relative gene expression between samples
using GAPDH as a housekeeping gene.2.8 | Histological evaluation of calcium deposition
within tissue fragments
After 4 weeks of tissue culture, tissue fragments were fixed in 4% para-
formaldehyde for 2 hr, dehydrated in graded ethanol, and embedded in
paraffin. Paraffin sections of 10 μm were prepared, mounted on
superfrost glass slides (Menzel, Braunschweig, Germany), stained with
freshly prepared 40‐mM alizarin red S (Sigma–Aldrich, St. Louis, USA)
solution, pH 4.1 for 10 min at RT, and finally washed with phosphate
buffered saline. Histological samples were dehydrated with 100%
ethanol and then cleared in Rothistol (Roth, Germany). After mounting
the samples with DPX (Merck, Germany), the slides were analysed and
photographed with a digital camera (AxioCam MRc5, Carl Zeiss, Jena,
Germany) under amicroscope (Axioscope40, Carl Zeiss, Jena, Germany)
using the Axiovision 40 software (Carl Zeiss, Jena, Germany).2.9 | Statistical analysis
Microsoft Excel 2010 and Prism 5.02 software (GraphPad Software,
San Diego, USA) were used for analysis of data. The results were
presented as mean ± standard error. Nine samples per group were
used for all assays. Measurements were performed in triplicate. In
order to detect statistical differences, we applied the Mann–Whitney
U‐test or Kruskal–Wallis test, depending on the number of compared
groups. Statistical significance was indicated by * for p < .05, ** for
p < .01, and *** for p < .001.3 | RESULTS
3.1 | Imaging of GFP‐transduced tissue fragments
under laser‐scanning confocal microscopy
Muscle with fascia revealed the highest number of green fluorescent
cells after transduction with different doses of an adenoviral vector
carrying the GFP cDNA. Muscle alone showed a well‐known, strong
background signal but less transduced cells after contact with
1 × 107, 5 × 107, or 1 × 108 pfu. Fat tissue samples displayed the
lowest number of transduced cells. It was possible to further increase
GFP expression in muscle with fascia with increasing doses of viral
vector. Transduction with 1 × 109 pfu resulted in the strongest signal
under laser scanning confocal microscopy indicating a very high level
of GFP gene expression (Figure 1).
FIGURE 1 Imaging of green fluorescent protein (GFP) transduced tissue fragments under laser‐scanning confocal microscopy. Adenoviral GFP‐
transduced tissue fragments were imaged with an inverted laser‐scanning confocal microscopy system 48 hr after transduction. Displayed is a
comparison of fat tissue, muscle tissue, and muscle with fascia transduced with 1 × 107 (a: fat; d: muscle; g: muscle with fascia), 5 × 107 (b: fat; e:
muscle; h: muscle with fascia), or 1 × 108 (c: fat; f: muscle; i: muscle with fascia) plaque forming units (pfu) of an adenoviral GFP vector. Additionally,
muscle with fascia was transduced with 2 × 108 (j), 4 × 108 (k), 6 × 108 (l), 8 × 108 (m), and 1 × 109 (n) pfu of adenoviral GFP vector. Scale
bar = 1,000 μm [Colour figure can be viewed at wileyonlinelibrary.com]
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transduction efficiency
Quantitative analysis further substantiated that, after transduction
with the same dose of Ad.GFP, muscle with fascia showed a
significantly larger area of green fluorescent cells compared to muscle
or fat. Muscle showed a significantly larger area of green fluorescent
cells than fat. All three tissues showed an increasing area of
GFP‐positive cells with increased doses of viral vector ranging from
1 × 107 to 1 × 108 pfu (Figure 2a). A further increase of green
fluorescent cell numbers was found when higher doses of GFP vectors
were applied to muscle with fascia ranging from 2 × 108 to 1 × 109 pfu.
Transduction with 1 × 109 pfu resulted in the largest area of
GFP‐positive cells, which was significantly higher than with all other
doses. 2 × 108 pfu induced the smallest area of green flourescent cells,
which is significantly smaller than the ones achieved with all other
doses. No significant differences were detected between doses
ranging from 4 × 108 to 8 × 108 pfu (Figure 2b).FIGURE 2 Quantitative analysis of adenoviral GFP‐transduction
efficiency. Ad.GFP‐transduction efficiency was analysed using Image
J software v.1.6, and the comparison was calculated utilizing Prism
software 5.02. (a) % GFP‐positive area of the three different tissues
with doses ranging from 1 × 107 to 1 × 108 pfu. (b) % GFP‐positive
area after transduction of muscle with fascia with doses ranging from
2 × 108 to 1 × 109 pfu. Values are presented as mean ± standard
error. The level of significance was indicated by * for p < .05, ** for
p < .01, and *** for p < .001 [Colour figure can be viewed at
wileyonlinelibrary.com]
283.3 | Proliferation determined by WST‐1 assay
The WST‐1 assay revealed that proliferation rate was reduced after
transduction with the adenoviral BMP‐2 vector as compared to
unmodified tissue. Increasing doses of viral vector led to a reduced
proliferation rate. Proliferation of fat tissue was significantly lower as
compared to muscle alone and muscle with fascia. Proliferation rate
of muscle with fascia was higher than muscle alone over the 4‐week
period, but a significant difference was detected only for the second
week of culture (p < .01), indicating an increased cell growth in
muscle with fascia. At 4 weeks, proliferation rate peaked for muscle
alone and muscle with fascia. Proliferation rates as determined
for muscle with fascia after 4 weeks in culture was as follows:
unmodified tissue = 129.70 ± 5.51; 1 × 107 = 115.80 ± 6.24;
5 × 107 = 72.47 ± 2.55; 1x108 = 63.74 ± 2.94. Lower proliferation
rates were observed for muscle alone at 4 weeks: unmodified
tissue = 124.60 ± 5.83; 1 × 107 = 103.40 ± 3.96; 5 × 107 =
66.80 ± 6.27; 1 × 108 = 58.43 ± 4.79. The lowest proliferation rate
was noted for fat tissue at 4 weeks: unmodified tissue = −0.02 ± 0.02;
1 × 107 = −0.05 ± 0.02; 5 × 107 = −0.06 ± 0.02; 1 × 108 = −0.26 ± 0.09
(Figure 3).3.4 | BMP‐2 production measured by an ELISA
Measurement of BMP‐2 concentrations by ELISA demonstrated that all
three types of tissue produced BMP‐2 for at least 30 days in vitro when
transducedwith doses of 1 × 107, 5 × 107, or 1 × 108 pfu. The increase of
the dose led to increased amounts of produced BMP‐2. Muscle with
fascia produced the highest levels of BMP‐2, and fat produced the low-
est levels. The peak of BMP‐2 content was seen at Day 9 for all three
types of tissue. At Day 9, transduction with 1 × 108 pfu led to
38.49 ± 1.89 ng/ml of BMP‐2 produced by muscle with fascia, which
was significantly higher than 24.37 ± 1.82 ng/ml of BMP‐2 produced
by muscle alone (p < .01) and 7.66 ± 0.58 ng/ml of BMP‐2 produced
by fat (p < .001). When transduced with higher doses of adenoviral
BMP‐2 vector ranging from 2 × 108 to 1 × 109 pfu, muscle with fascia
produced BMP‐2 at consistent high levels until Day 30. At Day 30,
the BMP‐2 concentrations in supernatants of muscle with
fascia after transduction with various doses of vector were as
follows: 1 × 107:6.56 ± 0.62 ng/ml; 5 × 107:10.44 ± 0.82 ng/ml;
1 × 108:14.11 ± 1.70 ng/ml; 2 × 108:13.81 ± 0.82 ng/ml;
4 × 108:29.28 ± 1.41 ng/ml; 6 × 108:22.81 ± 1.27 ng/ml;
8 × 108:26.60 ± 0.44 ng/ml; 1 × 109:27.53 ± 1.60 ng/ml. Concentrations
in supernatants of muscle alone on Day 30 were 5.38 ± 0.63 ng/ml
(1 × 107), 7.84 ± 0.35 ng/ml (5 × 107), and 10.74 ± 0.25 ng/ml
(1 × 108); concentrations of BMP‐2 in supernatants of fat tissue were
1.23 ± 0.06 ng/ml (1 × 107), 1.29 ± 0.06 ng/ml (5 × 107), and
1.51 ± 0.05 ng/ml (1 × 108). The highest concentration during thewhole
culture period was seen after transduction of muscle with fascia with
4 × 108 pfu at Day 18 (43.23 ± 2.31 ng/ml). Comparatively, transduction
with 4 × 108 and 1 × 109 pfu induced a significantly higher BMP‐2
expression thanwith other doses during the first 30 days, whereas a sig-
nificant difference between 4 × 108 and 1 × 109 pfu was observed only
at Days 6 and 18 (p < .05). The assay also revealed that muscle with fas-
cia secretes BMP‐2 for at least 90 days in vitro (Figures 4 and 5).
FIGURE 3 Proliferation determined by water‐soluble tetrazolium‐1 (WST‐1) assay. After 1, 2, 3, and 4 weeks of tissue culture, the ability of the
three types of tissue to proliferate was evaluated using a water‐soluble tetrazolium‐1 (WST‐1) assay. (a) Proliferation after 1 and 2 weeks. (b)
Proliferation after 3 and 4 weeks. Nine samples per group were analysed. Measurements were carried out in triplicate. Values are presented as
mean ± standard error. The level of significance was indicated by * for p < .05, ** for p < .01, and *** for p < .001
FIGURE 4 BMP‐2 produced by fat, muscle, and muscle with fascia determined by enzyme‐linked immunosorbent assay (ELISA). After transduction
of fat, muscle, and muscle with fascia with 1 × 107, 5 × 107, or 1 × 108 plaque forming units of an adenoviral BMP‐2 vector, BMP‐2 concentrations
in supernatants were determined by ELISA over 30 days. Nine samples per group were analysed. Measurements were carried out in triplicate.
Values are presented as mean ± standard error. The level of significance was indicated by * for p < .05, ** for p < .01, and *** for p < .001
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osteogenic differentiation
The analysis of gene expression by real‐time PCR demonstrated that
transduction with an adenoviral BMP‐2 vector led to overexpression
of the early osteogenic differentiation marker alkaline phosphatase
(ALP) and the late bone marker osteocalcin (OCN) in all three types
of tissue.
The highest ALP mRNA expression level was noted for muscle
tissue alone after transduction with 1 × 107, 5 × 107, and
1 × 108 pfu at two (11.16 ± 1.03; 19.46 ± 2.68; 43.98 ± 16.34) and four
(35.29 ± 1.70; 93.69 ± 2.48; 201.00 ± 12.94) weeks. ALP expression
levels in muscle with fascia were significantly lower with 5.43 ± 0.6429(p < .05), 7.21 ± 0.78 (p < .01), and 19.40 ± 3.44 (p < .05) at 2 weeks,
and 24.26 ± 2.13 (p < .05), 51.14 ± 2.29 (p < .001), and
97.98 ± 10.11 (p < .01) at 4 weeks. Fat tissue showed the lowest
ALP levels. The dose of 1 × 108 pfu induced a higher ALP expression
in all three types of tissue than the two lower doses, at 2 and 4 weeks.
Fat tissue showed a higher ALP expression at 2 weeks than at 4 weeks,
whereas ALP expression in muscle with fascia and muscle alone peaked
after 4 weeks of culture. Transduction of muscle with fascia with
additional doses of 2 × 108 to 1 × 109 pfu resulted in a further increase
of ALP expression (26.19 ± 2.10; 48.76 ± 6.51; 32.12 ± 1.21;
36.18 ± 5.28; 38.17 ± 6.30) respectively at 2 weeks, and
303.20 ± 16.67; 472.40 ± 19.61; 209.30 ± 22.16; 217.30 ± 9.15;
250.80 ± 10.80 respectively at 4 weeks). The highest level of ALP
FIGURE 5 BMP‐2 produced by muscle with fascia after transduction with higher doses of adenoviral vector determined by ELISA. Muscle with
fascia was transduced with 1 × 108, 2 × 108, 4 × 108, 6 × 108, 8 × 108, and 1 × 109 plaque forming units of an adenoviral BMP‐2 vector.
Concentrations of BMP‐2 in supernatants were determined by ELISA over 90 days. (a) Measurements from Day 6 until Day 30. (b) Measurements
from day 42 until day 90. Nine samples per group were analysed. Measurements were carried out in triplicate. Values are presented as
mean ± standard error. The level of significance was indicated by * for p < .05, ** for p < .01, and *** for p < .001
REN ET AL. 7mRNA expression in muscle with fascia was noted for the dose of
4 × 108 pfu of the adenoviral BMP‐2 vector especially at 4 weeks
(p < .001).
After transduction with 1 × 107, 5 × 107, and 1 × 108 pfu, the
highest OCN mRNA expression levels at 2 weeks were noted for mus-
cle alone (5.51 ± 0.23, 11.71 ± 0.45, and 14.92 ± 0.49, respectively),
which was significantly higher than for muscle with fascia at 5 × 107
(6.58 ± 0.50, p < .001) and 1 × 108 (7.32 ± 0.39, p < .001). After
4 weeks, however, the OCN expression levels after transduction with
1 × 107, 5 × 107, and 1 × 108 pfu were not significantly different
between muscle with fascia and muscle alone. Fat tissue showed the
lowest OCN expression at 2 weeks (0.15 ± 0.02; 0.25 ± 0.02;
0.55 ± 0.06, respectively) and 4 weeks (0.25 ± 0.02; 0.29 ± 0.02;
0.51 ± 0.03, respectively), and a significant difference was noticed in
comparison to muscle alone (p < .001) and muscle with fascia
(p < .001). In all three types of tissue, the dose of 1 × 108 pfu induced
a higher OCN expression than 1 × 107 and 5 × 107 pfu, at 2 and
4 weeks. The higher doses of 4 × 108 and 1 × 109 pfu used for
transduction of muscle with fascia resulted in the highest levels
of OCN mRNA expression in muscle with fascia at 2 weeks
(4 × 108:27.24 ± 1.29; 1 × 109:26.20 ± 1.76) and 4 weeks
(4 × 108:15.61 ± 1.03; 1 × 109:17.16 ± 2.13), and no significant
difference was observed between 4 × 108 and 1 × 109 (Figure 6).3.6 | Histological evaluation of calcium deposition
within tissue fragments
Calcium deposition was detected by alizarin‐red staining of tissue
sections after 4 weeks of tissue culture. BMP‐2 transduction induced
mineralization of muscle with fascia and muscle alone, but not fat30tissue. Calcium deposition was visible in the superficial zones of tissue
discs. Unmodified control tissue samples did not exhibit any minerali-
zation. When transduced with 1 × 108 pfu, muscle with fascia and mus-
cle alone showed a similar extension of mineralization. Most calcium
deposition in muscle with fascia was detected after transduction with
a dose of 4 × 108 pfu of the adenoviral BMP‐2 vector (Figure 7).4 | DISCUSSION
It is well documented that genetically modified stem cells can be used
to deliver growth factors to the site of tissue injuries. In particular,
there is a large number of studies suggesting that stem cells derived
from bone marrow, muscle, and adipose tissue are capable of inducing
bone growth when transduced with an osteogenic gene (Lee et al.,
2002; Lieberman et al., 1999; Peterson et al., 2005). In an attempt to
simplify ex vivo gene therapy for tissue engineering, a novel strategy
involving the use of gene‐activated tissue grafts was developed (Betz
et al., 2009; Betz et al., 2010). This method allows to effectively
restore bone defects in preclinical animal models utilizing autologous
muscle or fat tissue as biological, three‐dimensional, degradable
scaffolds delivering progenitor cells and osteogenic molecules to an
osseous lesion.
In order to further improve this technology, we identified fascia as
another interesting tissue structure that could serve as an osteo‐
regenerative drug delivery system supporting endogenous repair of
bone. Fascia is a sheet of connective tissue consisting primarily of
collagen with a large number of fibroblasts residing on the surface.
Our data indicate that these cells can be transduced effectively when
applying an adenoviral vector to the surface of fascia. In contrast, there
FIGURE 7 Histological evaluation of calcium deposition within tissue fragments. After 4 weeks of tissue culture, histological sections of fat,
muscle, and muscle with fascia were stained with alizarin red in order to detect calcium deposition. Representative cross‐sections of samples
transduced with 1 × 108 plaque forming units (pfu) of an adenoviral BMP‐2 vector and unmodified control samples are shown. Transduction with
4 × 108 pfu induced the strongest osteogenic response in muscle with fascia. Fat: (a) 1 × 108 pfu, (b) unmodified control; muscle: (c) 1 × 108 pfu, (d)
unmodified control; muscle with fascia: (e) 4 × 108 pfu, (f) 1 × 108 pfu, (g) unmodified control. Scale bar = 1,000 μm [Colour figure can be viewed at
wileyonlinelibrary.com]
FIGURE 6 Quantitative real‐time PCR analysis of osteogenic differentiation. Expression levels of osteogenic markers after transduction of fat,
muscle, and muscle with fascia with various doses of an adenoviral BMP‐2 vector was analysed by quantitative real‐time PCR at 2 and 4 weeks.
(a) Alkaline phosphatase (ALP) mRNA expression. (b) Osteocalcin (OCN) mRNA expression. Expression levels were normalized to mRNA levels for
GAPDH. Nine samples per group were analysed. Measurements were carried out in triplicate. Values are presented as mean ± standard error. The
level of significance was indicated by * for p < .05, ** for p < .01, and *** for p < .001
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REN ET AL. 9are fewer cells on the surface of muscle and fat tissue fragments that
can be transduced with the same adenoviral vector leading to a
reduced production of GFP and BMP‐2. This suggests that fascia can
enhance delivery of the transgene leading to larger amounts of
osteogenic growth factor locally as shown by the presented data
generated by ELISA.
Wong et al. explored the characteristics of rat fascia‐derived stem
cells (Wong et al., 2015). Cells were isolated from rat fascia and
stimulated to differentiate into the chondrogenic, osteogenic, and
adipogenic lineage. The results from this study show that rat fascia‐
derived stem cells possess high chondrogenic but a lower osteogenic
and adipogenic potential as compared to bone marrow‐derived stem
cells and adipose‐derived stem cells. In our present study, the potential
of muscle with fascia to differentiate into the osteogenic lineage was
significantly higher than that of adipose tissue. Importantly, it must
be noted that no osteogenic supplements were added to the culture
medium as we intended to solely study the effect of BMP‐2 expression
levels and its effects on the different tissues. This, and the fact that we
investigated the behaviour of tissue fragments instead of isolated cells,
might explain why the results of other differentiation studies vary.
When preparing the tissue fragments, we took great care that no
fascia was attached to the “muscle alone samples.” We cannot
completely exclude that there was any deep fascia within the inner
parts of the “muscle alone” fragments. However, the important differ-
ence between “muscle alone” and “muscle with fascia” for transduction
was the surface of the fragments. “Muscle with fascia” samples were
completely covered on one side with fascia resulting in higher trans-
duction efficiency. The question whether the osteogenic differentia-
tion capacity or the potential to deliver high levels of transgene is
more important for effective bone regeneration can only be answered
by future in vivo experiments. Interestingly, recent in vitro studies
could prove that human fat tissue (Bondarava et al., 2017) and human
muscle tissue (Miao et al., 2017) can transdifferentiate into mineralized
tissue with bone‐like characteristics. These results suggest that the
grafted gene‐activated tissue fragments used in the experiments of
Betz and colleagues (Betz et al., 2009; Betz et al., 2010) contributed
to the formation of new bone in vivo through transdifferentiation
and not only through the local effects of the delivered BMP on the
environment of the lesion. The secreted BMPs seem to induce bone
growth via combined effects of graft transdifferentiation as well as
recruitment, proliferation, and differentiation of progenitor cells
residing in the proximity of the osseous defect. For these reasons, it
becomes obvious that much effort must be put into the development
of appropriate drug delivery systems. With respect to BMPs and bone
repair, such improved delivery methods are of particular interest
because large amounts of recombinant human BMP‐2 applied clinically
led to adverse side effects in humans (James et al., 2016). Instead of
introducing milligrams of BMP‐2 into the body, gene transfer leads to
a local production of only nanogram quantities of BMP‐2 within the
bony lesion.
The harvest and transplantation of fascia alone or in combination
with muscle is a common procedure frequently performed by plastic
and reconstructive surgeons in order to cover soft tissue defects and
reconstruct deformities (Lee et al., 2016; Nuri, Ueda, & Yamada,
2016; Veyrat, Verillaud, Herman, & Bresson, 2016). Based on the32results of our present work, we hypothesize that muscle with fascia
genetically modified to overexpress BMP‐2 could also serve as an
osteo‐regenerative implant repairing large bone defects. The combina-
tion of muscle with fascia might be an advantageous graft for bone
repair because it delivers larger amounts of BMP‐2 as compared to
fat and muscle alone while still showing a high osteogenic differentia-
tion capacity. The dose of 4 × 108 pfu of an adenoviral BMP‐2 vector
seems to be optimal for transduction leading to both high levels of
BMP‐2 production and effective osteogenic differentiation.
The promising data of the present in vitro study encourage to
carry out an in vivo experiment evaluating the effect of BMP‐2
gene‐activated muscle with fascia on the regeneration of large bone
defects in a well‐established preclinical model.
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Summary 
Current cell-based strategies for the treatment of large segmental bone defects remain far 
from ideal. The extraction and expansion of autologous stem cells, as well as the complexity 
of scaffold fabrication are significant obstacles for their clinical application. Previous studies 
have demonstrated that bone morphogenetic protein-2 (BMP-2) genetically engineered fat or 
muscle tissue could achieve sustained delivery of BMP-2 and bone healing in vivo.  Aim 1 of 
my thesis was to investigate whether the fat tissue graft is capable of transdifferentiation into 
bone or merely serves as a protein delivery vehicle in previous transduction studies 
(Publication 1). Part 2 of my thesis explored BMP-2 expression profiles in gene activated fat 
tissue, muscle tissue, and muscle with fascia tissue under various transduction dosages, 
aiming to optimize this tissue-based molecular signals delivery system (Publication 2). 
In the first study, human fat tissue fragments were cultured in normal growth medium or 
osteogenic medium with or without the stimulus of recombinant BMP-2, BMP-7 or BMP-9 
for 4 weeks. Calcium deposition analysis, RT-PCR, and immunofluorescence of bone 
markers were performed to detect osteogenic differentiation in fat tissue. Osteogenic 
differentiation was induced when fat tissue fragments were cultured in osteogenic medium, 
and the addition of recombinant BMPs further increased calcium deposition, ALP and OCN 
mRNA expressions, as well as bone marker protein expressions. Our study demonstrated that 
fat tissue is capable to undergo osteogenic transdifferentiation without stem cells isolation. 
This finding encourages the conversion of cell-based tissue engineering approaches to tissue-
based approaches, which will greatly simplify current bone regeneration strategies.  
In the second part of my thesis (Publication 2), fat tissue, muscle tissue, and muscle with 
fascia tissue were harvested from rats and transduced with different adenoviral vector doses 
encoding human BMP-2 (Ad.hBMP-2). The proliferation, BMP-2 expression and osteogenic 
differentiation were analyzed by WST-1, ELISA and RT-PCR. The comparison of fat tissue, 
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muscle tissue and muscle with fascia tissue transduced by Ad.hBMP-2 under the same dose 
revealed, that muscle with fascia exhibited the highest BMP-2 expression. The transduction 
dose at 4 × 108 plaque forming units (pfu) appeared to be optimal for transduction of muscle 
with fascia. 
Fascia of muscle remarkably enhanced BMP-2 protein expression after gene transduction, 
showing a high potential as an improved osteo-regenerative implant facilitating endogenous 
repair. Considering that 4 × 108 pfu has been indicated as the optimal dose for gene 
transduction, future in vivo studies should focus on investigating the osteogenic 
transdifferentiation capacity of muscle with fascia under such a transduction dose as well as 
the potential of human fat tissue fragments for the regeneration of bone defects. 
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Zusammenfassung 
Aktuelle, zellbasierte Strategien zur Behandlung segmentaler Knochendefekte kritischer 
Größe bedürfen der weiteren Optimierung. Die Entnahme und Vermehrung autologer Zellen 
sowie die Komplexität der Herstellung von optimalen Trägermaterialien sind nach wie vor 
signifikante Hindernisse für den erfolgreichen Einsatz als klinische Anwendung. 
Vorhergehende Studien konnten zeigen, dass Fett- und Muskelgewebe, nach Transduktion 
mit Bone Morphogenic Protein-2 (BMP-2) Genen, zu einer ausreichend langen Expression 
des osteogenen Wachstumsfaktors führt, um Knochendefekte kritischer Größe in vivo zu 
regenerieren. Der erste Teil meiner Doktorarbeit beschäftigt sich mit der Frage, ob humanes 
Fettgewebe durch osteogene Stimulation in der Lage ist in Knochen oder knochenähnliches 
Gewebe zu transdifferenzieren oder ob das transduzierte Fettgewebe der früheren Studien 
vorwiegend als Wirkstofflieferant diente (Publikation 1). Teil 2 meiner Arbeit beschäftigt 
sich mit der Optimierung von gentransduziertem Fett-, Muskel- und Fasziengewebe . Hierbei 
war das Ziel, sowohl optimale Dosierung des Vektors als auch das am besten geeignete 
Gewebe zu identifizieren (Publikation 2). 
Im ersten Teil meiner Arbeit (Publikation 1) wurden humane Fettgewebefragmente in 
normalen Zellkultur Medium sowie in osteogenem Medium allein oder mit zusätzlichem 
Stimulus durch die rekombinanten Wachstumsfaktoren BMP-2, BMP-7 oder BMP-9 über die 
Dauer von vier Wochen kultiviert. Die Bewertung der ostogenen Differenzierung erfolgte 
mittels Analyse der Kalziumeinlagerung sowie der Expression von Knochenmarkern mittels 
real-time PCR und Immunofluoreszenz. Osteogene Differenzierung konnte in den 
Fettgewebefragmenten, die in ostogenem Medium kultiviert wurden, nachgewiesen werden. 
Die Zugabe von rekombinanten BMP’s führte zu einem höheren Grad der osteogenen 
Differenzierung. Dies zeigte sich in höherer Kalziumeinlagerung sowie der verstärkten 
Expression der Knochenmarker. Das Ergebnis dieser Studie zeigt, dass humanes Fettgewebe 
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osteogen differenziert werden kann ohne eine vorherige Isolation und Kultivierung von 
Stammzellen durchzuführen und deutet darauf hin, dass ein Wechsel von einer zellbasierten 
Regeneration zu einer gewebebasierten Regeneration möglich ist. Dies würde eine 
Anwendung stark vereinfachen und die Chancen eines breiten klinischen Einsatzes deutlich 
verbessern.  
Im zweiten Teil meiner Arbeit (Publikation 2) wurde Fett- und Muskelgewebefragmente mit 
und ohne Fasziengewebe von Ratten entnommen und anschließend mit verschieden 
adenoviralen Dosen mit dem BMP-2 Gen transduziert. Die Proliferation, BMP-2 Expression 
und osteogene Differenzierung wurden mit Hilfe eines WST-1 Tests, ELISA bzw. der real-
time PCR untersucht. Der Vergleich der BMP-2 Expression von Fett-, Muskel- und Muskel 
mit Faziengewebefragmenten nach Transduktion mit der identischen Vektordosis ergab die 
höchste BMP-2 Expression in der Muskelgewebe mit Faszien Gruppe. Eine Vektordosis von 
4 x 108 plaque forming units (pfu) stellte sich als optimale Dosierung heraus. Das Ergebnis 
zeigt das Potential von Muskelfazien für eine effektive Wirkstoffexpression zur Optimierung 
des Regenerationspotential von Gewebeimplantaten. Für weiterführende Studien sollte 
sowohl die als optimale Dosis ermittelte Vektormenge in Verbindung mit den 
Muskelfazienimplantaten sowie das Potential der humanen Fettgewebefragmente für die 
Knochendefektregeneration  in vivo untersucht werden. 
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